Astria Therapeutics Completes Underwritten Offering of Common Stock
Astria Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases, completed its underwritten registered direct offering of 10,340,000 shares of its common stock. The shares were priced on January 30, 2024 at an offering price of $12.09 per share and the offering closed on February 1, 2024. Astria received gross proceeds of approximately $125 million before deducting underwriting discounts and commissions and other offering expenses.
The WilmerHale team representing Astria consisted of
Rosemary Reilly,
Molly Fox,
Jeffries Oliver-Li,
Andrea Sorrentino,
Kevin Cheng and
Arpi Youssoufian, with assistance from
Heidi Treiber,
Ben Lobley and Mark Devine.
